The long-term trend of the EPS is a vital number as it helps understand the future potential of Psychemedics Corporation. The EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 4.20 % over the last twelve months. EPS growth is a vital measure of execution of the strategy for Psychemedics Corporation since it indicates how well the business is allocating resources to benefit shareholders.

Psychemedics Corporation is in the medical diagnostics and research industry and healthcare sector. The company CEO is Raymond C. Kubacki. Psychemedics Corp provides testing services for the detection of drugs of abuse through the analysis of hair samples. This information is useful to employers for both applicant and employee testing, as well as to physicians and among others.

Previous Intraday Performance:

The PMD shares had a previous change of -2.07% which opened at 17.31 and closed at 17.01. It moved to an intraday high of 17.60 and a low of 16.91.

SeekingAlpha:  Psychemedics goes ex-dividend tomorrow

Historical Performance:

Over the last five trading days, PMD shares returned -1.39% and in the past 30 trading days it returned -3.88%. Over three months, it changed -11.73%. In one year it has changed -11.91% and within that year its 52-week high was 22.88 and its 52-week low was 16.11. PMD stock is 5.59% above its 52 Week Low.

Our calculations result in a 200 day moving average of 19.38 and a 50 day moving average of 17.93. Right now, PMD stock is trading -12.21% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Psychemedics goes ex-dividend tomorrow


The company has a market cap of $93.7m with 5.5m shares outstanding and a float of 4.6m shares. Trading volume was 3,081 shares and has experienced an average volume of 13,122 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Psychemedics Corporation was 1.1 which ended on 31st of December 2017, which according to the previous close, that is a PE of 15.46.

Below was the last reported quarterly earnings per share:
09-30-2018:  0.23
06-30-2018:  0.21
03-31-2018:  0.23
12-31-2017:  0.22

The dividend per share is currently 0.72, which is a dividend yield of 4.23%. PMD stock may not have sufficient earnings to cover future dividends and still be able to invest in and grow the business, therefore in the future the dividend may be reduced.

Base on our calculations, the intrinsic value per share is 24.79, which means it might be undervalued and has a margin of safety of 31.38%

Indicators Also to Watch:

Based on the latest filings, there is 63.20% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.

I calculated the beta to be 0.73

PR Newswire:  Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 34.03%, return on assets is 23.20%, profit margin is 14.05%, price-to-sales is 2.26 and price-to-book is 5.06.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 5  : Financial Safety Result
 4  : Past Performance Result
 3  : Valuation Result
 4  : Dividend Safety Result
 3  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here